Mon Jun 16 00:00:00 UTC 2025: Here’s a summary of the article and a rewritten version as a news article:

**Summary:**

India aims to become a global leader in AI-driven biomanufacturing, leveraging its existing strength in generic drug production. Government initiatives like the BioE3 Policy and the IndiaAI Mission are designed to foster innovation and ethical AI development. While AI is already transforming aspects of biomanufacturing, from drug screening to optimizing production processes, the country’s regulatory framework needs to catch up. Concerns exist around data governance, intellectual property, and ensuring AI systems are reliable and contextually appropriate for India’s diverse conditions. The article argues for a risk-based, adaptive regulatory framework, investment in infrastructure and talent, and collaboration between stakeholders to unlock the full potential of AI in biomanufacturing.

**News Article:**

**India Aims to Lead in AI-Powered Biomanufacturing, But Regulatory Hurdles Loom**

**NEW DELHI (June 16, 2025)** – India is positioning itself to become a global powerhouse in AI-driven biomanufacturing, building on its established reputation as a leading producer of generic drugs and vaccines. Government initiatives like the BioE3 Policy and the IndiaAI Mission are fueling this ambition, aiming to foster innovation while prioritizing ethical AI development.

AI is already transforming the sector, with companies like Biocon and Strand Life Sciences leveraging AI for drug screening, personalized medicine, and optimizing manufacturing processes. AI’s role extends to predictive maintenance, improved clinical trials, and even drug discovery. The goal is to produce more effectively and efficiently, reduce waste, and improve healthcare outcomes.

However, experts warn that India’s regulatory framework, designed for a pre-AI era, is struggling to keep pace with the rapid advancements. Concerns are mounting around data governance, intellectual property rights, and ensuring the reliability and contextual relevance of AI systems across diverse environments.

“While India’s ambitions are sky-high, its regulatory framework is still catching its breath,” said Deepakshi Kasat, a scientist with GlaxoSmithKline.

The article points to the European Union’s AI Act and the U.S. FDA’s guidance as examples of risk-based and adaptive regulations that India should emulate. The absence of adequate oversight could lead to flawed AI systems making inaccurate decisions, lost revenue and a blow to India’s reputation for quality.

The article emphasizes the need for:

* A risk-based regulatory framework tailored to AI applications in biomanufacturing.
* Increased investment in infrastructure and skilled talent.
* Enhanced collaboration between regulators, industry, academia, and international partners.

If India successfully addresses these challenges, it could unlock significant economic and social benefits, solidifying its position as a leader in the future of biomanufacturing and AI-driven healthcare solutions.

Read More